Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
  1. Homepage
  2. Equities
  3. China
  4. Shanghai Stock Exchange
  5. Sinocelltech Group Limited
  6. Summary
    688520   CNE100003ZL3

SINOCELLTECH GROUP LIMITED

(688520)
End-of-day quote Shanghai Stock Exchange  -  2023-01-31
70.62 CNY   +0.18%
2022Sinocelltech's COVID-19 Vaccine Wins Nod For Emergency Use in China; Shares Slump 11%
MT
2022Sinocelltech to Invest $34 Million in New Australian Unit; Shares Up 5%
MT
2022Sinocelltech Cleared to Launch Clinical Trial for COVID-19 Vaccine
MT
 SummaryQuotesChartsNewsCalendarCompanyFinancialsFunds 
Quotes 5-day view   End-of-day quote. End-of-day quote Shanghai Stock Exchange
01/19/2023 01/20/2023 01/30/2023 01/31/2023 02/01/2023 Date
74.5 75.28 75.7 70.49 70.62 Last
1274581 1476773 2249027 4174129 2182240 Volume
+2.26% +1.05% +0.56% -6.88% +0.18% Change
Estimated financial data (e)
Sales 2020 0,33 M 0,05 M 0,05 M
Net income 2020 -713 M -106 M -106 M
Net cash position 2020 381 M 56,5 M 56,5 M
P/E ratio 2020 -26,2x
Yield 2020 -
Sales 2021 134 M 19,9 M 19,9 M
Net income 2021 -867 M -129 M -129 M
Net Debt 2021 727 M 108 M 108 M
P/E ratio 2021 -29,4x
Yield 2021 -
Capitalization 32 042 M 4 753 M 4 753 M
EV / Sales 2020 59 264x
EV / Sales 2021 195x
Nbr of Employees 1 353
Free-Float 19,1%
More Financials
Company
Sinocelltech Group Ltd is a China-based company mainly engaged in the research, development and industrialization of biopharmaceutical products. The Company focuses on monoclonal antibodies, recombinant proteins and vaccine products. Its main products are SCT800, SCT200, SCT-I10A, SCT400, SCT510, SCT1000 and SCT630, among others. The Company is also engaged in asset leasing business and payment collection business. 
More about the company
All news about SINOCELLTECH GROUP LIMITED
2022Sinocelltech's COVID-19 Vaccine Wins Nod For Emergency Use in China; Shares Slump 11%
MT
2022Sinocelltech to Invest $34 Million in New Australian Unit; Shares Up 5%
MT
2022Sinocelltech Cleared to Launch Clinical Trial for COVID-19 Vaccine
MT
2022Sinocelltech Raises $67 Million From Share Placement
MT
2022Sinocelltech Group Limited Reports Earnings Results for the Nine Months Ended September..
CI
2022Sinocelltech Group Limited Reports Earnings Results for the Half Year Ended June 30, 20..
CI
2022Sinocelltech Group Limited Reports Earnings Results for the First Quarter Ended March 3..
CI
2022Sinocelltech Group Limited Reports Earnings Results for the Full Year Ended December 31..
CI
2021Sinocelltech Group Limited(SHSE:688520) added to Shangha..
CI
2021Sinocelltech Group Limited Reports Earnings Results for the Nine Months Ended September..
CI
2021Sinocelltech Group Limited Reports Earnings Results for the Half Year Ended June 30, 20..
CI
2021Sinocelltech Group Limited(SHSE:688520) added to Shangha..
CI
2021Sinocelltech Group Limited(SHSE:688520) added to Shangha..
CI
2021Sinocelltech Group Limited Reports Earnings Results for the First Quarter Ended March 3..
CI
2021Sinocelltech Group Limited announced that it expects to receive CNY 3.960737 billion in..
CI
More news
News in other languages on SINOCELLTECH GROUP LIMITED
2022Le Groupe Sinocelltech Limited annonce ses résultats pour les neuf mois terminés le 30 ..
2022Le Groupe Sinocelltech Limited annonce ses résultats pour le semestre terminé le 30 jui..
2022Le Groupe Sinocelltech Limited annonce ses résultats pour le premier trimestre clos le ..
2022Le Groupe Sinocelltech Limited annonce ses résultats pour l'année complète se terminant..
2021Sinocelltech Group Limited annonce ses résultats pour les neuf mois terminés le 30 sept..
More news
Chart SINOCELLTECH GROUP LIMITED
Duration : Period :
Sinocelltech Group Limited Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends SINOCELLTECH GROUP LIMITED
Short TermMid-TermLong Term
TrendsBullishNeutralNeutral
Income Statement Evolution
Managers and Directors
Liang Zhi Xie Chairman & General Manager
Gui Fen Zhao Chief Financial Officer & Director
Xun Li Chairman-Supervisory Board
Zhi Guo Su Independent Director
Xiao Chuan Wang Independent Director
Sector and Competitors
1st jan.Capi. (M$)
SINOCELLTECH GROUP LIMITED16.53%4 665
VERTEX PHARMACEUTICALS11.88%81 440
REGENERON PHARMACEUTICALS, INC.5.06%80 956
WUXI APPTEC CO., LTD.15.90%40 901
BIONTECH SE-4.77%34 764
BEIGENE, LTD.15.61%26 436